Regeneron antibody cocktail cut COVID-19 deaths in some cases: research
Oxford University on Wednesday released a study that found that a COVID-19 antibody cocktail created by Regeneron reduces the risk of death due to the coronavirus.
The treatment known as REGEN-COV, which was granted emergency use authorization in the U.S. in November, was found to be able to neutralize the COVID-19 virus’s ability to infect cells. The treatment uses a combination of the monoclonal antibodies casirivimab and imdevimab.
Of the patients that were observed in the study, the Regeneron cocktail reduced mortality by one-fifth among patients who were seronegative — had not developed an antibody response to the virus yet — when compared to similar patients who received normal care.
The researchers estimated, based on their observations, that treatment with Regeneron would result in six fewer deaths for every 100 patients who received the cocktail.